ReviewOncology letters2018
Emerging function of N6-methyladenosine in cancer.
Review in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- A novel biclustering algorithm for mining m6A co-methylation patterns based on beta-binomial distribution and data screening strategy.PLoS computational biology · 2026Article
- Epigenetic regulation in female reproduction: the impact of m6A on maternal-fetal health.Cell death discovery · 2025Review
- Comprehensive Review and Assessment of Computational Methods for Prediction of N6-Methyladenosine Sites.Biology · 2024Review
- Review
- m6A regulates breast cancer proliferation and migration through stage-dependent changes in Epithelial to Mesenchymal Transition gene expression.Frontiers in oncology · 2023Article
- TMAO Promotes NLRP3 Inflammasome Activation of Microglia Aggravating Neurological Injury in Ischemic Stroke Through FTO/IGF2BP2.Journal of inflammation research · 2023Article
- N6-methyladenosine related gene expression signatures for predicting the overall survival and immune responses of patients with colorectal cancer.Frontiers in genetics · 2023Article
- The prognostic value of m6A-related LncRNAs in patients with HNSCC: bioinformatics analysis of TCGA database.Scientific reports · 2022Article
- Bioinformatics Analysis of the Characteristics and Correlation of m6A Methylation in Breast Cancer Progression.Contrast media & molecular imaging · 2022Article
- Expression and prognostic significance of m6A-related genes in TP53-mutant non-small-cell lung cancer.Journal of clinical laboratory analysis · 2022Article
- Article
- Dual effects of NMolecular therapy. Nucleic acids · 2021Review
- The role of RNA mRespiratory research · 2021Article
- Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism.Molecular therapy oncolytics · 2021Article
- RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma.Journal of cellular and molecular medicine · 2021Article
- The Role of RNA Methylation in Regulating Stem Cell Fate and Function-Focus on mStem cells international · 2021Review
- Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.Frontiers in immunology · 2021Article
- Significance of N6-Methyladenosine RNA Methylation Regulators in Immune Infiltrates of Ovarian Cancer.Frontiers in genetics · 2021Article
- Comprehensive Analysis of the Immune-Oncology Targets and Immune Infiltrates ofFrontiers in cell and developmental biology · 2021Article
- HBXIP promotes gastric cancerAging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyladenosine (m6A) modification in RNA has been implicated in diverse biological processes including the maintenance of embryonic stem cells, early development and diseases. Although the m6A modification was discovered several decades ago, its biological function remained unclear. The recent discovery of enzymes responsible for 'writing' or 'erasing' the modification and single-nucleotide resolution mapping by next-generation sequencing technology have revealed its function in biological processes. Its enrichment pattern is conserved in mammalian transcriptomes, and the level of m6A is tightly regulated by methyltransferases (writers), demethylases (erasers) and binding proteins (readers). Furthermore, accumulating evidence suggests that the aberrant regulation of m6A turnover is associated with multiple types of cancer including acute myeloid leukemia, breast cancer, glioblastoma, lung cancer and liver cancer. Studies have demonstrated that factors involved in m6A metabolism serve either oncogenic or tumor-suppressor roles in different contexts. The previous studies of the role of m6A in cancer biology are discussed in the present review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.